Unjha Formulations Peer Comparison

BSE: 531762

₹32.00

₹0.00 (0.00%)

As on 17-Sep-2026 10:58IST

Market cap

₹14 Cr

Revenue (TTM)

₹15 Cr

P/E Ratio

30.5

P/B Ratio

3.6

Div. Yield

0 %

Edit

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Market cap (₹ Cr)	14	36,657	32,845	29,196	29,064
Revenue (₹ Cr)	15	9,683	3,564	1,936	2,372
Net Profit (₹ Cr)	0.47	1,018.97	414.00	288.22	497.77
Net Margin (%)	3.05	10.47	11.23	14.79	20.72
RoE (%)	11.48	21.30	8.38	29.77	28.49
Price to Earnings	30.51	36.24	80.30	101.30	58.39
Price-To-Book	3.58	7.01	6.52	21.75	14.38

Income Statement (₹ Cr)

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Operating Revenue	15.42	9,683.45	3,564.00	1,935.80	2,371.81
Total Income	15.42	9,730.84	3,686.00	1,948.58	2,402.61
Total Expenditure	14.55	7,739.53	2,792.00	1,485.56	1,608.91
EBITDA	0.88	1,943.92	772.00	450.24	762.90
Depreciation	0.15	425.10	226.00	50.83	98.11
EBIT	0.73	1,518.82	546.00	399.41	664.79
Interest	0.01	148.45	217.00	40.84	26.33
Other Income	0.00	47.39	122.00	12.78	30.80
Exceptional Items	0.00	-27.85	12.00	0.00	0.00
Profit before Tax	0.72	1,389.91	463.00	371.35	669.26
Provision for Tax	0.25	370.94	49.00	83.14	171.48
Profit after Tax	0.47	1,018.97	414.00	288.22	497.77

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Shareholder's Funds	3.84	4,950.03	4,940.00	1,288.82	1,874.47
Minority Interest	0.00	-7.58	-5.00	0.00	0.00
Non-Current Liabilities	0.00	723.57	1,712.00	202.03	345.47
Current Liabilities	1.67	3,912.24	1,622.00	835.87	710.20
Total Liabilities	5.51	9,514.48	8,578.00	2,326.71	2,930.14

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Non-Current Assets	1.30	3,392.16	5,343.00	519.60	1,290.62
Current Assets	4.21	5,612.10	2,606.00	1,681.81	1,483.13
Total Assets	5.51	9,514.48	8,578.00	2,326.71	2,930.14
Total Debt*	0.00	1,204.08	2,125.00	259.37	196.61
Net Current Assets	2.55	1,699.86	984.00	845.94	772.93
Contingent Liabilities	8.80	258.92	768.26	19.09	13.18

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Cash From Operating Activities	1.24	943.55	390.00	205.05	346.68
Cash Flow from Investing Activities	-0.23	-1,193.06	-241.00	-409.72	-423.73
Cash from Financing Activities	-0.01	343.43	-54.00	283.07	20.98
Net Cash Inflow / Outflow	1.00	93.92	95.00	78.39	-56.08

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
ROCE (%)	27.54	25.25	6.79	29.22	27.50
ROE (%)	11.48	21.30	8.38	29.77	28.49
ROA (%)	9.34	11.42	4.94	24.77	19.48
EBIT Margin (%)	4.71	15.68	15.32	20.63	28.03
Net Margin (%)	3.05	10.47	11.23	14.79	20.72
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Revenue Growth (%)	12.94	18.36	18.37	46.65	78.33
EBIT Growth (%)	231.51	30.43	252.26	62.13	303.07
Net Profit Growth (%)	379.59	32.39	377.85	89.49	182.61
EPS Growth (%)	379.59	36.68	1,001.33	78.60	277.72
Book Value Growth (%)	22.45	11.36	13.47	144.31	22.95

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Price / Earnings	30.51	35.50	82.42	99.74	58.39
Price / Book Value	3.58	7.01	6.52	21.75	14.38
Dividend Yield (%)	0.00	0.19	0.00	0.09	0.15
EV/EBITDA	14.49	19.40	44.44	64.65	37.89
Market Cap (₹ Cr)	9.09	30,257.56	19,071.62	12,753.19	15,412.11

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Debt to Equity	0.00	0.05	0.31	0.11	0.09
Short term debt to equity ratio	--	0.16	0.09	0.05	--
Current Ratio	2.53	1.43	1.61	2.01	2.09
Quick Ratio	2.15	0.82	1.06	1.14	1.37
Interest Coverage	103.71	10.36	3.13	10.09	26.41

	Unjha Formulations	Emcure Pharmaceuticals	Wockhardt	Rubicon Research	Neuland Lab
Debtors to sales (%)	8.74	26.46	16.50	26.28	22.82
Asset Turnover	3.06	1.09	0.43	1.66	0.93
Receivable days	33.45	88.68	58.75	40.13	77.32
Inventory Days	19.48	84.11	75.82	60.29	80.83
Payable days	37.68	176.65	186.21	232.47	125.94
Cash Conversion Cycle	15.25	-3.86	-51.64	-132.04	32.22

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.